Neuromuscular Disorders

An overview of the developments in ALS research 1:15
An overview of the developments in ALS research
Matthew Kiernan • 4 Apr 2022
Efgartigimod in patients with generalized myasthenia gravis: ADAPT and ADAPT+ 7:04
Efgartigimod in patients with generalized myasthenia gravis: ADAPT and ADAPT+
James F. Howard Jr. • 12 Apr 2022
Important developments in understanding the mechanisms of ALS 1:47
Important developments in understanding the mechanisms of ALS
Matthew Kiernan • 4 Apr 2022
Treating spinal muscular atrophy in adult patients 3:13
Treating spinal muscular atrophy in adult patients
Anna Kostera-Pruszczyk • 25 Jun 2022
Recommended standards of care for adult patients with spinal muscular atrophy 2:26
Recommended standards of care for adult patients with spinal muscular atrophy
Anna Kostera-Pruszczyk • 25 Jun 2022
Personalizing therapy: the future of ALS treatment 1:48
Personalizing therapy: the future of ALS treatment
Nigel Leigh • 17 Mar 2022
Developing biomarker panels for ALS diagnosis 2:53
Developing biomarker panels for ALS diagnosis
Nigel Leigh • 17 Mar 2022
Changing our approach to ALS clinical trial design 3:44
Changing our approach to ALS clinical trial design
Nigel Leigh • 17 Mar 2022
MIROCALS: low-dosage IL-2 for the treatment of ALS 2:13
MIROCALS: low-dosage IL-2 for the treatment of ALS
Nigel Leigh • 17 Mar 2022
Assessing the role of measuring plasma neurofilament light levels in ALS 1:58
Assessing the role of measuring plasma neurofilament light levels in ALS
Nigel Leigh • 17 Mar 2022
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis 2:05
Long term safety and efficacy data for ravulizumab in AChR Ab+ generalized myasthenia gravis
James F. Howard Jr. • 12 Apr 2022
Correlation between synaptic density and cognitive issues in ALS 6:28
Correlation between synaptic density and cognitive issues in ALS
Anna Sanchez Avila • 8 Mar 2022
How can the gut microbiome modulate the peripheral and brain immune systems? 4:45
How can the gut microbiome modulate the peripheral and brain immune systems?
Giulio Pasinetti • 18 Mar 2022
Improving ALS diagnosis: the Gold Coast criteria and the role of TMS 2:44
Improving ALS diagnosis: the Gold Coast criteria and the role of TMS
Matthew Kiernan • 4 Apr 2022
Ex vivo gene therapy for neurodegenerative diseases 2:20
Ex vivo gene therapy for neurodegenerative diseases
Clive Svendsen • 15 Mar 2022
Unanswered questions in ALS research 1:44
Unanswered questions in ALS research
Clive Svendsen • 15 Mar 2022
The content of VJNeurology is intended for healthcare professionals